Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
  • A61L24/001—Use of materials characterised by their function or physical properties
  • A61L24/0026—Sprayable compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
  • A61L24/001—Use of materials characterised by their function or physical properties
  • A61L24/0042—Materials resorbable by the body
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
  • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
  • A61L24/043—Mixtures of macromolecular materials

Definitions

• the present invention relates generally to medical adhesives and to methods of tissue closure, and, especially, to medical adhesives and to methods of tissue adhesion in which a mixture of isocyanate functional molecules or prepolymers is applied to tissue.
• Traumatic wounds rival respiratory tract infections as the most common reason people seek medical care.
• Conventional methods of tissue closure have several substantial limitations, including inability to produce fluid-tight closure, unsuitability for microsurgical applications, necessity for a second operation for removal, increased probability of inflammation and infection, and significant scarring and tissue injury during insertion.
• Medical tapes have been used for some applications, but medical tapes are limited by weak strength and problems with adherence to tissue. Treatment of lacerations with sutures often involves the injection of local anesthetic and use of needles, which can distress an already frightened patient.
• tissue adhesives have been developed.
• Applications of adhesives to biological tissue range from soft (connective) tissue adhesion to hard (calcified) tissue adhesion.
• Soft tissue adhesives are, for example, used both externally and internally for wound closure and sealing.
• Hard tissue adhesives are used, for example, to bond prosthetic materials to teeth and bone.
• Four main mechanisms of adhesion have been proposed for such tissue adhesives, including, mechanical interlocking, adsorption, diffusion theory, and electronic theory. Mechanical interlocking involves the penetration of the bonding agent into surface irregularities or porosity in the substrate surface as means for adhesion.
• Adsorption theory relies on the fact that if intimate interfacial molecular contact is achieved, interatomic and intermolecular forces will establish a strong joint. Diffusion theory states that the adhesion of polymers to substrates and each other requires mutual diffusion of polymer molecules or segments across the interface. Lastly, electronic theory suggests that electronic transfer between adhesive and adherent may lead to electrostatic forces that result in high intrinsic adhesion.
• tissue adhesives have significant limitations.
• biological tissue adhesives such as fibrin glues are effective in some uses, but are extremely expensive because they are derived from autologous tissue.
• Fibrin glue also suffers from relatively weak tensile strengths and labor-intensive means of production.
• fibrinogen and thrombin obtained from human blood pose the risk of viral infection with, for example, acquired immune deficiency syndrome and/or hepatitis.
• Cyanoacrylate macromonomers polymerize upon contact with water via chemistry similar to that used in well known "superglues".
• the use of the cyano-acrylate group in cyanoacrylate polymers limits the versatility of the formulation, and other functional groups in the material must be compatible with the hypersensitive cyanoacrylate.
• Use of acrylate-functional polyethylene glycols allows for sealing and degradation (upon incorporation of lactic acid or glycolic acid repeat units in the polyethylene glycol precursor).
• curing requires the use of UV or other radiation. Given the penetration depth limitations of the light, radiation cure limits the use of this technology to thin films that are readily accessible to the light source.
• the present invention provides a method of applying an adhesive to organic tissue.
• the method includes the step of applying a mixture of molecules to the organic tissue.
• the mixture of molecules includes molecules having terminal isocyanate functional groups.
• the mixture of molecules has an average isocyanate functionality of at least 2.1 to enable crosslinking (or curing). More preferably, the average isocyanate functionality of the mixture is at least 2.5.
• the mixture of molecules preferably has a viscosity in the range of approximately 1 to approximately 100 centipoise to, for example, allow for ready application to tissue over a temperature range of use (typically, approximately 0°C to approximately 40°C). More preferably, the viscosity is in the range of approximately 1 to approximately 50 centipoise over a temperature range of use. In general, the mixture of molecules must be applicable or spreadable at the temperature of use.
• the mixture of molecules forms a crosslinked polymer network or cures upon contact with the organic tissue in the presence of water. Sufficient water is generally present upon or within organic tissue and addition of water is not typically required for curing.
• the crosslinked polymer network is biocompatible and biodegradable. The crosslinked polymer network biodegrade into molecules or degradation products that are biocompatible.
• the mixture of molecules includes lysine tri-isocyanate or a lysine tri-isocyanate derivative (for example, lysine tri-isocyanate ethyl ester).
• the mixture of molecules includes isocyanate capped molecules formed by reacting multi-isocyanate functional molecules with multi-functional precursor molecules including terminal functional groups selected from the group consisting of a hydroxyl group, a primary amino group and a secondary amino group.
• multi-functional refers to a compound that has two (di-functional) or more functionalities. Polyurethane prepolymers can thereby be formed.
• the multi-functional precursor compounds are biocompatible.
• multi-amine functional precursors of the multi-isocyanate functional molecules are also biocompatible.
• the multi-amine functional precursors of the multi-isocyanate functional molecules can, for example, be biocompatible amino acids or biocompatible derivatives of amino acids.
• the multi-functional precursor molecules can, for example, include at least one of polyethylene glycol, a polyamino acid (typically, greater than 50 linked amino acids and including, for example, proteins and/or polypeptides), an aliphatic polyester (including, for example, polylactic acid, polyglycolic acid and/or polycaprolactone), a saccharide (including, for example, a sugar), a polysaccharide (for example, starch), an aliphatic polycarbonate, a polyanhydride, a steroid (for example, hydrocortisone), glycerol, ascorbic acid, an amino acid (for example, lysine, tyrosine, serine, and/or tryptophan), or a peptide (typically, 2 to 50 linked amino acids).
• a polyamino acid typically, greater than 50 linked amino acids and including, for example, proteins and/or polypeptides
• an aliphatic polyester including, for example, polylactic acid, polyglycolic
• the multi-functional precursor molecules include polyethylene glycol and the multi-isocyanate functional molecules include at least one of lysine di-isocyanate ethyl ester or lysine tri-isocyanate ethyl ester.
• the multi-functional precursor molecules can further include a sugar such as glucose.
• the polyethylene glycol preferably has number average molecular weight less than 10,000. More preferably, the polyethylene glycol has number average molecular weight less than 2,000. Most preferably, the polyethylene glycol has number average molecular weight less than 1,000. In several embodiments of the present invention, the polyethylene glycol has a number average molecular weight in the range of approximately 50 to approximately 1000.
• the mixture of molecules of the present invention forms a crosslinked polymer network in less than two minutes. More preferably, the mixture of molecules forms a cross-linked polymer network in less than one minute.
• the crosslinked polymer network resulting from curing of the mixture of molecules of the present invention upon contact with organic tissue preferably biodegrades in a period of time during which healing occurs.
• the crosslinked polymer network preferably retains intact to adhere the tissue of a laceration or an incision until healing has sufficiently progressed that the wound or incision remains closed.
• the crosslinked polymer network biodegrades to lose at least approximately 2/3 of its material in approximately 7 to approximately 30 days, and, more preferably in approximately 7 to approximately 14 days.
• the present invention provides an adhesive including a mixture of isocyanate capped molecules formed by reacting multi-isocyanate functional molecules with multi-functional precursor molecules including terminal functional groups selected from the group consisting of a hydroxyl group, a primary amino group and a secondary amino group.
• the functional groups are hydroxyl groups.
• the multifunctional precursor compounds are biocompatible.
• Multi-amine functional precursors of the multi-isocyanate functional molecules are also biocompatible.
• the mixture of molecules preferably has an average isocyanate functionality of at least 2.1 and, more preferably, has an average isocyanate functionality of at least 2.5.
• the mixture of molecules preferably has a viscosity in the range of approximately 1 to approximately 100 centipoise.
• the mixture of molecules forms a crosslinked polymer network upon contact with the organic tissue in the presence of water.
• the crosslinked polymer network is biocompatible and biodegradable.
• the crosslinked polymer network degrades into degradation products including the precursor molecules and the multi-amine functional precursors.
• the present invention provides an adhesive including a mixture of isocyanate capped prepolymers formed by reacting multi-isocyanate functional molecules with multi-functional precursor molecules including terminal functional groups selected from the group consisting of a hydroxyl group, a primary amino group and a secondary amino group.
• the multi-functional precursor compounds are biocompatible.
• multi-amine functional precursors of the multi-isocyanate functional molecules are biocompatible.
• At least one of the multi-functional precursors is a flexible biocompatible polymer having a number average molecular weigh of at least 50.
• the mixture of prepolymers has an average isocyanate functionality of at least 2.1.
• the mixture of prepolymer is a non-solid that is preferably spreadable for application to tissue over the temperature range of use.
• the mixture of prepolymers forms a crosslinked polymer network upon contact with the organic tissue in the presence of water.
• the crosslinked polymer network is biocompatible and biodegradable.
• the crosslinked polymer network degrades into degradation products including the precursor molecules and the multi-amine functional precursors.
• the adhesives of the present invention present the possibility of chemically (covalently) bonding to the tissue.
• reactive isocyanate groups on the adhesive can react with reactive groups such as hydroxyl groups or free amine groups in the tissue to form a covalent bond (that is, a urethane bond or a urea bond).
• the isocyanate groups also form a crosslinked polymeric network in the presence of moisture inherently present in and on tissue.
• the adhesives of the present invention, the biodegradable crosslinked polymer network formed therefrom and the biodegradation products of that polymer network are preferably biocompatible.
• biodegradable refers generally to the ability of the adhesive to be broken down (especially into innocuous degradation products) over time in the environment of use.
• biocompatible refers generally to compatibility with living tissue or a living system.
• the adhesives, polymer networks and degradation products of the present invention are preferably substantially nontoxic and/or substantially non-injurious to the living tissue or living system in the amounts required over the period of contact/exposure. Moreover, such materials preferably do not cause a substantial immunological reaction or rejection in the amounts required over the period of contact/exposure.
• the adhesives of the present invention have relatively strong tensile strengths and form a relatively strong bond to tissue, while reducing or eliminating problems such as cytotoxicity, low degradation rates and inflammation associated with many current adhesives.
• the adhesives and methods of the present invention provide a minimally invasive avenue to, for example, tissue closure, with generally no mechanical damage to tissue and a decreased probability of infection.
• the adhesives of the present invention are relatively easy to synthesize and do not require the use of potentially harmful solvents
• the present invention provides biocompatible and biodegradable lysine-di-isocyanate- (LDI-) or lysine-tri-isocyanate- (LTI-) based urethane polymers/prepolymers suitable for use as tissue adhesive.
• the LDI-polyurethane adhesives or glues are, for example, easily synthesized from LDI, polyethylene glycol (sometime referred to as PEG) and glucose without solvent.
• the degradation products are lysine, PEG, glucose and ethanol.
• the LDI-polyurethane tissue adhesives and other adhesives of the present invention reduce time required in wound repair, provided a flexible water-resistant protective coating and eliminate the necessity of suture removal.
• the LDI-polyurethane tissue adhesives and other tissue adhesives of the present invention are relatively easy to use following appropriate and common wound preparation as compared to currently available skin adhesives.
• the adhesives of the present invention are more convenient to use than conventional repair methods such a suture because, for example, patients, and especially children, are more likely to accept the idea of being "glued" over such conventional or traditional methods of repair.
• the modulus or stiffness of the LDI-based polyurethane tissue adhesives and other tissue adhesives of the present invention can be readily adjusted for use either as soft (connective) tissue adhesives (for example, as skin adhesives to replace sutures and staples for closure of certain lacerations and/or incisions) and as hard (calcified) tissue adhesives (for example, as bone or dental adhesives) in both humans and animals.
• Figure 1 illustrates the general structure of a isocyanate capped prepolymer of the present invention.
• Figure 2 illustrates the chemical structures of lysine di-isocyanate (LDI), lysine tri-isocyanate (LTI), polyethylene glycol (PEG) and glucose.
• Figure 3 illustrates examples of the chemical structure of LDI capped glucose, LDI capped polyethylene glycol and a LDI capped LLD-PEG-glucose prepolymer.
• Figure 4A illustrates a container encompassing an adhesive of the present invention in which substantially all or all of the functional groups of the molecules of the adhesive are capped with isocyanate functionality.
• Figure 4B illustrates a dual-compartment container in which one compartment includes a mixture of molecules/prepolymers having an excess of hydroxyl (and/or amine) functionality and the other compartment includes a mixture of molecules/prepolymers having an excess of isocyanate (-NCO) functionality.
• a tissue adhesive is preferably a liquid or in another spreadable form (for example, a fluid-like gel) for application to the tissue.
• the adhesive also preferably solidifies relatively quickly when applied and binds to living tissues in the presence of moisture.
• the tissue adhesive is also preferably nonirritating locally and nontoxic systematically in the amount required to achieve an effective tissue adhesion.
• appropriate flexibility and degradability are required for the cured adhesive in, for example, wound closure so the adhesive does not disturb healing.
• the tissue adhesives of the present invention satisfy those criteria.
• the adhesives of the present invention include a mixture of molecules having terminal isocyanate functional groups.
• the mixture of molecules has an average isocyanate functionality of greater than 2 (per molecule or chain), and preferably greater than 2.1 to enable crosslinking (or curing). More preferably, the average isocyanate functionality of the mixture is at least 2.5.
• the adhesives of the present invention are preferably applied as a mixture of isocyanate capped polymers/prepolymers. A general depiction of an example of such a molecule is illustrated in Figure 1.
• Such prepolymers can, for example, be formed by reacting multi-isocyanate functional molecules with multi-functional precursor molecules including terminal functional groups selected from the group consisting of a hydroxyl group, a primary amino group and a secondary amino group.
• the functional groups are hydroxyl groups.
• the isocyanate caps of a molecule such as represented in Figure 1 enable crosslinking and may enhance adhesion to tissue by covalently bonding to hydroxyl groups and amine groups in the tissue.
• the precursor compounds which react with multi-isocyanate functional molecules to form the "middle" or interior chain section(s) of such molecules are preferably chosen to enable control of physical properties such as the viscosity of the adhesive and the elasticity of the cured polymer network.
• the physical properties of the cured polymer network can be controlled by the overall or average functionality of the adhesive (average number of isocyanate end groups per chain), the molecular weight between crosslinks (that is, the molecular weight between isocyanate groups in the prepolymer), the aromatic content of the prepolymer for certain prepolymers including aromatic groups (incorporated, for example, through addition of the biocompatible amino acid tyrosine), and the number of hydrogen bonding groups (for example, urea groups and urethane groups) in the prepolymer.
• increasing the functionality through, for example, use of higher quantities of an isocyanate-capped sugar in the precursor leads to a crosslinked polymer network with relatively higher modulus (stiffness).
• Biocompatible compounds or molecules chosen for the middle or interior chain sections can also be chosen to impart other desirable properties to the adhesives.
• an active enzyme protein
• an aqueous solution of protein to a urethane prepolymer prompts incorporation of the protein (covalently) into the polyurethane network (via reaction of free amines on the protein with the terminal isocyanate groups).
• a steroid such as hydrocortisone (which has been incorporated into an adhesive of the present invention) can be incorporated to act as, for example, an anti-inflammatory.
• lysine di-isocyanate ethyl ester or LDI (synthesized via the phosgenation of the ethyl ester of lysine) or lysine tri-isocyanate LTI; glucose (including five hydroxyl functional groups) and polyethylene glycol or PEG (including two hydroxyl function groups).
• the isocyanate groups of the LDI or LTI form prepolymer chain via reaction with the hydroxyl groups of the glucose and the PEG.
• FIG. 3 illustrates representative examples of isocyanate- (LDI-) capped glucose, isocyanate- (LDI-) capped PEG and an isocyanate- (LDI-) capped PEG-glucose-LDI prepolymer molecule.
• Lysine di-isocyanate which is a volatile compound, is rendered non-volatile through incorporation into the polymeric precursors of the present invention (hence, LDI is not present, but is rather locked into a macromonomer).
• the adhesive is thus simply a polyurethane prepolymer, that is, a polyurethane precursor where all reactive end groups (amine and hydroxyl) have been capped with, for example, lysine di-isocyanate, leaving numerous terminal isocyanate groups and preferably little or no free hydroxyl or amine groups (to prevent further reaction) in the prepolymer.
• Exposure of such a prepolymer to tissue can result in covalent bonding of the polymer to the tissue through the reaction of free amine groups or hydroxyl groups with the isocyanate groups in the prepolymer. Further, water will also react with the isocyanate groups, liberating CO and forming additional free amine groups, which ultimately react with isocyanates to form crosslink points.
• the number of crosslinking points was controlled primarily via the concentration of glucose, which includes five hydroxyl groups. Using a relatively high concentration of glucose increases crosslinking points and increases the modulus of the crosslinked polymer network.
• a biocompatible, generally flexible polymer such as PEG acts, in part, as a spacer. Increasing the molecular weight of the PEG used in the adhesives of the present invention increases the distance between crosslinking points and decreases the modulus of the crosslinked polymer network
• polyurethanes including adhesives
• adhesives are generated from aromatic isocyanates. Their rate of degradation is not sufficiently fast for use in-vivo (as biodegradable adhesives) and the byproducts of degradation of commercially available polyurethane adhesives include toxic aromatic diamines.
• Lysine di-isocyanate was generated via phosgenation of the ethyl ester of lysine in the presence of pyridine. Unlike lysine or its ethyl ester, LDI is volatile and hence is readily purified via distillation at reduced pressure.
• ester group acts as an in-situ acid catalyst to speed hydrolysis of the urethane linkages.
• Bone marrow stromal cells (BSMC's) from New Zealand white rabbits were seeded on the glycerol/LDI foams, and were observed to adhere and spread.
• BMSC's produced collagen (as found through measurement of hydroxy pro line) at levels commensurate with control cells.
• glucose-LDI foams were implanted in New Zealand white rabbits. Samples of the material and surrounding tissue were removed after two months. Fewer giant cells, for example, were observed in these samples than in control samples using polylactic acid/glycolic acid copolymers.
• the polymeric foams described above were generally highly crosslinked materials. Once formed, these materials could not be reprocessed. Linear polymers from LDI and di-functional polyethylene glycols (molecular weights from 200 to 8000) were also synthesized. While such polymer were processable, the polymers dissolved in water. Extension of the "hard" segment of those polyurethanes to produce thermoplastic elastomers (i.e., processable yet water-insoluble polymers) was accomplished via the use of tyrosine, lysine, or tryptophan as chain extenders. In such studies, an excess ⁇ of LDI was added to the other amino acid. The resulting LDI-amino acid-LDI compound was then reacted with the polyethylene glycol) The use of the chain extended hard segment allowed generation of processable polyurethanes from LDI that did not dissolve in water.
• crosslinked materials described above are generally not preferred for use as adhesives although they can be applied as such in the manner described in connection with Figure 4B below. Nonetheless, the above studies indicated that (a) isocyanate-terminal prepolymers are readily synthesized, (b) polymer foams generated from LDI and either glucose or glycerol degrade over a period of 2-3 months, generating primarily lysine and the hydroxy-functional precursor, (c) bone marrow stromal cells readily attach and thrive on polymer foams generated from LDI, (d) LDI-glucose polymers produce a mild immune reaction in-vivo.
• Preferred embodiments of the adhesives of the present invention include mixtures of isocyanate capped prepolymers that are suitably functionalized to crosslink upon application to tissue as described above.
• a prepolymer can incorporate a multi-isocyanate functional molecule such as LDI or LTI as described above, a molecule such as glycerol or a sugar that is relatively highly functionalize (having at least three reactive functional groups) to create crosslink points, and a spacer molecule/group such as PEG which must be at least di-functional for incorporation into the interior chain of the prepolymer.
• the spacer is preferably a polymer of a number average molecular weight of at least 50 that, when increased in concentration relative to the other components of the prepolymer, acts to lower the viscosity of the adhesive and/or to decrease the modulus of the cured polymer network.
• substantially all or all of the functional groups of the molecules of the adhesive are capped/functionalized with iscyanate functionality to prevent further reaction.
• at least a stoichimetric amount of isocyanate functionality and, preferably, an excess of isocyanate functionality is used durning synthesis.
• such an adhesive of the present invention in which substantially all or all of the functional groups of the molecules of the adhesive are capped with isocyanate functionality
• extended storage can also be achieved using a dual-compartment container in which one compartment includes a mixture of molecules/prepolymers having an excess of hydroxyl (and/or amine) functionality and the other compartment includes a mixture of molecules/prepolymers having an excess of isocyanate (-NCO) functionality.
• the container can include a mixing unit or element as known in the art to mix the contents of each compartment upon application to tissue to create a crosslinked polymer network.
• a representative LDI-based polyurethane tissue adhesive or glue was synthesized using the procedure described below. To generate the adhesive, 0.5889 gram glucose (3.27 mmol, -OH 16.36 ⁇ nol) was added to 5 ml of PEG 400 (14.09 mmol, -OH 28.18 mmol) in a dry round-bottomed flask, flushed with nitrogen and heated at 50°C to make a clear solution. PEG is a liquid at room temperature and solubilized the glucose without the need for additional solvent.
• Another LDI-based polyurethane tissue was synthesized by the following procedure using PEG 200 rather than PEG 400, which ultimately generated a seal that was stiffer and exhibited greater strength than the adhesive of Example 1.
• 0.6 gram glucose (3 mmol, -OH 15 mmol) was added to 5 ml of PEG 200 (28.18 mmol, -OH 56.35 mmol) in a dry round-bottomed flask, flushed with nitrogen and heated at 50°C to make a clear solution.
• Example 3 illustrated that when the portion of glucose was increased in the reaction mixture, the time needed for closing the wound was shorter, the bond strength increased, and the ultimate material was stiffer.
• 1.8 gram glucose (10 mmol, - OH 50 mmol) was added to 5 ml of PEG 200 (28.18 mmol, -OH 56.35 mmol) in a dry round- bottomed flask, flushed with nitrogen and heated at 50°C to make a clear solution.
• 10 ml of LDI (d 1.157, FW 226, 51.19 mmol, -NCO 102.02 mmol) was added.
• the flask was fitted with a rubber septa and sealed.
• the reaction mixture was stirred at 50°C for 48 hr, and a viscous solution was obtained.
• the glue was kept at room temperature under nitrogen until use. The viscous liquid was spread onto each of two pieces of moist tissue, which when pressed together would adhere firmly to each other after approximately 1 minute
• Example 3 the procedure of Example 3 was generally followed, except that the study substituted PEG 200 with PEG 400.
• 1.8 gram glucose (10 mmol, -OH 50 mmol) was added in 10 ml of PEG 400 (28.18 mmol, -OH 56.35 mmol) in a dry round- bottomed flask, flushed with nitrogen and heated at 50°C to make a clear solution.
• 10 ml of LDI (d 1.157, FW 226, 51.19 mmol, -NCO 102.39 mmol) was added, and the flask was fitted with a rubber septa and sealed.
• Example 5 The reaction mixture was stirred at 50°C for 48 hr, and a viscous solution was obtained. The solution was kept at room temperature under nitrogen until use. The viscous liquid was spread onto each of two pieces of moist tissue, which when pressed together adhered firmly to each other after approximately 1 minute. [0052] Example 5
• Lysine tri-isocyanate was substitued for lysine di-isocyanate.
• Lysine tri-isocyanate can be obtained commercially, or synthesized via (a) generating the aminoamide derivative of lysine via the coupling of ethylene diamine (large excess) to lysine using any one of a number of carbodiimides, followed by (b) phosgenation.
• LTI lysine tri-isocyanate
• Example 5 the procedure of Example 5 was generally follwed, exepct that PEG 400 (instead of PEG 200) was reacted with LTI.
• the material set-up time was the same as that of LTI-glucose-PEG 200.
• 0.229 gram glucose (1.27 mmol, - OH 6.36 mmol) was added in 5 ml of PEG 400 (14.1 mmol, -OH 28.2 mmol) in a dry round- bottomed flask, flushed with nitrogen and heated at 50°C to make a clear solution.
• Solution A was made from 2.15 g PEG 200 (10.75 mmol, -OH 21.5 mmol) and 4.4 ml of LDI (d 1.157, FW 226, 22.53 mmol, -NCO 45.05 mmol) after 48 hr of reaction.
• Solution B was made from 4.2 g PEG 200 (21 mmol, -OH 42 mmol) and 2.2 ml of LDI (11.26 mmol -NCO 22.52 mmol) after 48 hr of reaction.
• both A and B solutions could be stored for long periods of time.
• the same volume of each solution was mixed well to use as a glue. Once the A and B solutions were mixed thoroughly (1:1 ratio by volume), the viscous liquid was spread onto each of two pieces of moist tissue. When pressed together, the tissue pieces adhered firmly to each other after 2 minutes.
• Solution A was made from 4 g PEG 400 (10 mmol, -OH 20 mmol) and 4 ml of LDI (d 1.157, FW 226, 20.48 mmol, -NCO 40.96 mmol) after 48 hr of reaction.
• Solution B was made from 8 g PEG 400 (20 mmol, -OH 40 mmol) and 2 ml of LDI (10.23 mmol -NCO 20.48 mmol) after 48 hr of reaction. Because solution A had excess LDI in the reaction mixture, and solution B had excess PEG 400 in the reaction mixture, both solutions A and B were easy to store for long periods of time.
• Solution A was made from 0.9 g glucose (5 mmol, 25mmol -OH) to 5 ml of PEG 200 (28.18 mmol, -OH 56.35 mmol, total -OH 81.35 mmol) and 16 ml of LDI (d 1.157, FW 226, 81.9 mmol, -NCO 163.82 mmol) after 48 hr of reaction.
• Solution B was made from 1.8 g glucose (10 mmol, -OH 50 mmol) in 10 ml of PEG 200 (56.35 mmol, -OH 112.7 mmol, total -OH 162.7 mmol) and 8 ml of LDI (40.96 mmol -NCO 81.91 mmol) after 48 hr of reaction. Because solution A had excess -NCO in the reaction mixture, and solution B had excess -OH in the reaction mixture, both solutions A and B were easy to store for long periods of time. The same volume of each solution was mixed well to use as skin glue. Once the A and B solutions were mixed thoroughly (1:1 ratio by volume), the viscous liquid was spread onto each of two pieces of moist tissue. When pressed together the tissue pieces adhered firmly to each other after approximately 2 minutes.
• gelatin was used with an LDI-polyurethane adhesive of the present invention.
• the set-up or cure time was found to be shorter than when the LDI-based polyurethane adhesive was used without gelatin.
• 100 ⁇ l of 0.1% gelatin (Type A: from porcine skin, 300 bloom, Sigma Co.) was mixed with 0.5 ml of the LDI-based polyurethane from Example 1. This viscous liquid was spread onto each of two pieces of moist tissue, which when pressed together adhered firmly to each other after approximately 10 - 30 seconds.

Landscapes

• Health & Medical Sciences (AREA)
• Surgery (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Materials Engineering (AREA)
• Materials For Medical Uses (AREA)
• Adhesives Or Adhesive Processes (AREA)
• Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
• Polyurethanes Or Polyureas (AREA)
• Biological Depolymerization Polymers (AREA)
• Polyethers (AREA)

Priority Applications (12)

Applications Claiming Priority (1)

Publications (1)

Family

ID=34958183

Family Applications (1)

Country Status (12)

Cited By (21)

Families Citing this family (13)

Citations (4)

Family Cites Families (5)

• 2004
  • 2004-05-27 CN CN200480043348.3A patent/CN1968718B/zh not_active Expired - Fee Related
  • 2004-05-27 RU RU2006144819/15A patent/RU2346704C2/ru not_active IP Right Cessation
  • 2004-05-27 EP EP04753573A patent/EP1755693A1/en not_active Withdrawn
  • 2004-05-27 BR BRPI0418804-7A patent/BRPI0418804A/pt not_active Application Discontinuation
  • 2004-05-27 CA CA2576223A patent/CA2576223C/en not_active Expired - Fee Related
  • 2004-05-27 MX MXPA06013721A patent/MXPA06013721A/es active IP Right Grant
  • 2004-05-27 NZ NZ550970A patent/NZ550970A/en not_active IP Right Cessation
  • 2004-05-27 WO PCT/US2004/016767 patent/WO2005118011A1/en active Application Filing
  • 2004-05-27 JP JP2007515009A patent/JP2008500095A/ja active Pending
  • 2004-05-27 AU AU2004320265A patent/AU2004320265B2/en not_active Ceased
• 2006
  • 2006-11-17 ZA ZA200609694A patent/ZA200609694B/xx unknown
  • 2006-11-27 IL IL179643A patent/IL179643A0/en unknown

Patent Citations (4)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events